[HTML][HTML] Antibody and B cell responses to SARS-CoV-2 infection and vaccination: the end of the beginning
As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
[HTML][HTML] A Covid-19 milestone attained—a correlate of protection for vaccines
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
[HTML][HTML] Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
EC Abebe, TA Dejenie - Frontiers in Immunology, 2023 - frontiersin.org
Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends the
body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their …
body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their …
[HTML][HTML] XBB. 1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG. 5.1 and emerging XBB variants
N Patel, JF Trost, M Guebre-Xabier, H Zhou… - Scientific Reports, 2023 - nature.com
Abstract Monovalent SARS-CoV-2 Prototype (Wuhan-Hu-1) and bivalent (Prototype+ BA.
4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity …
4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity …
Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial
Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
[HTML][HTML] Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
G Kenny, S O'Reilly, N Wrigley Kelly, R Negi… - Nature …, 2023 - nature.com
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from
early vaccine trials suggested binding antibody thresholds could serve as surrogate markers …
early vaccine trials suggested binding antibody thresholds could serve as surrogate markers …
[HTML][HTML] Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50 …
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50 …
[HTML][HTML] Principles and therapeutic applications of adaptive immunity
Adaptive immunity provides protection against infectious and malignant diseases. These
effects are mediated by lymphocytes that sense and respond with targeted precision to …
effects are mediated by lymphocytes that sense and respond with targeted precision to …
[HTML][HTML] Immunogenicity and safety of AZD2816, a beta (B. 1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously …
MN Ramasamy, EJ Kelly, S Seegobin, PI Dargan… - The Lancet …, 2023 - thelancet.com
Background This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine
expressing the full-length SARS-CoV-2 beta (B. 1.351) variant spike protein that is otherwise …
expressing the full-length SARS-CoV-2 beta (B. 1.351) variant spike protein that is otherwise …